Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: Drug-target interaction analyses

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 4, 2014, Pages 10-20

  Kakuta, Hirotoshi ^a   Kurosaki, Eiji ^a   Niimi, Tatsuya ^a   Gato, Katsuhiko ^a   Kawasaki, Yuko ^a   Suwa, Akira ^a   Honbou, Kazuya ^a   Yamaguchi, Tomohiko ^a   Okumura, Hiroyuki ^a   Sanagi, Masanao ^a   Tomura, Yuichi ^a   Orita, Masaya ^a   Yonemoto, Takako ^b   Masuzaki, Hiroaki ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b Shizuoka Prefectural General Hospital   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3T3-L1 CELLS; ADIPOCYTES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CALORIMETRY; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PARTIAL AGONISM; MEMBRANES, ARTIFICIAL; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PPAR GAMMA; PROTEIN BINDING; SURFACE PLASMON RESONANCE;

EID: 84896479832     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.211722     Document Type: Article

References (65)

1. Abuissa H, Jones PG, Marso SP, and O'Keefe JH Jr (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821-826.
2. Amano Y, Yamaguchi T, Ohno K, Niimi T, Orita M, Sakashita H, and Takeuchi M (2012) Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertens Res 35:715-719.
3. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, and Yoshimatsu H (2006) Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48:51-57.
4. Avdeef A (2012). Permeability-PAMPA, in Absorption and Drug Development: Solubility, Permeability, and Charge State, 2nd ed, pp 319-498, Wiley, New York.
5. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, and Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43:993-1002.
6. Busetto L (2001) Visceral obesity and the metabolic syndrome: effects of weight loss. Nutr Metab Cardiovasc Dis 11:195-204.
7. de Luis DA, Conde R, González-Sagrado M, Aller R, Izaola O, Dueñas A, Pérez Castrillón JL, and Romero E (2010) Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. Nutr Hosp 25:275-279.
8. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz Md, Moller DE, and Berger J (1996) Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ 1 and γ 2. Biochem Biophys Res Commun 224: 431-437.
9. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, and Desvergne B (2001) Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142:4195-4202.
10. Frost SC and Lane MD (1985) Evidence for the involvement of vicinal sulfhydryl groups in insulin-activated hexose transport by 3T3-L1 adipocytes. J Biol Chem 260:2646-2652.
11. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, and Hayashi T, et al. (2004) An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett 576:492-497.
12. Fujisaka S, Usui I, Kanatani Y, Ikutani M, Takasaki I, Tsuneyama K, Tabuchi Y, Bukhari A, Yamazaki Y, and Suzuki H, et al. (2011) Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice. Endocrinology 152:1789-1799.
13. Furukawa H, Mawatari K, Koyama K, Yasui S, Morizumi R, Shimohata T, Harada N, Takahashi A, and Nakaya Y (2011) Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes. Eur J Pharmacol 660: 485-491.
14. Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW, Jr, Hashim MA, Hull-Ryde EA, and Kaldor I, et al. (1998) N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 41:5020-5036.
15. Holdgate G, Geschwindner S, Breeze A, Davies G, Colclough N, Temesi D, and Ward L (2013). Biophysical methods in drug discovery from small molecule to pharmaceutical, In Protein-Ligand Interactions (Williams MA and Daviter T, eds) pp 327-355 Humana Press, Totowa, NJ.
16. Ishii-Yonemoto T, Masuzaki H, Yasue S, Okada S, Kozuka C, Tanaka T, Noguchi M, Tomita T, Fujikura J, and Yamamoto Y, et al. (2010) Glucocorticoid reamplification within cells intensifies NF-κB and MAPK signaling and reinforces inflammation in activated preadipocytes. Am J Physiol Endocrinol Metab 298:E930-E940.
17. Israili ZH (2000) Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14(Suppl 1):S73-S86.
18. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, and Cooper ME (2005) Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23:463-473.
19. Janke J, Engeli S, Gorzelniak K, Luft FC, and Sharma AM (2002) Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51:1699-1707.
20. Jitrapakdee S, Slawik M, Medina-Gomez G, Campbell M, Wallace JC, Sethi JK, O'Rahilly S, and Vidal-Puig AJ (2005) The peroxisome proliferator-activated receptor-g regulates murine pyruvate carboxylase gene expression in vivo and in vitro. J Biol Chem 280:27466-27476.
21. Kajiya T, Ho C, Wang J, Vilardi R, and Kurtz TW (2011) Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 29:2476-2483.
22. Kakuta H, Sudoh K, Sasamata M, and Yamagishi S (2005) Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 25:41-46.
23. Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, and Naka T (1996) Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 39: 5228-5235.
24. Lakshmanan AP, Watanabe K, Thandavarayan RA, Sari FR, Harima M, Giridharan VV, Soetikno V, Kodama M, and Aizawa Y (2011) Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action. Free Radic Res 45:575-584.
25. Lamounier-Zepter V, Ehrhart-Bornstein M, and Bornstein SR (2006) Insulin resistance in hypertension and cardiovascular disease. Best Pract Res Clin Endocrinol Metab 20:355-367.
26. Lind L, Berne C, and Lithell H (1995) Prevalence of insulin resistance in essential hypertension. J Hypertens 13:1457-1462.
27. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, and Ouchi N, et al. (2001) PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099.
28. Marino MR, Langenbacher KM, Ford NF, Raymond RH, Manning J, Vesterqvist O, Shamblen EC, and Lasseter KC (1999) Pharmacodynamics and pharmacokinetics of irbesartan in patients with mild to moderate hypertension. J Cardiovasc Pharmacol Ther 4:67-75.
29. Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, and Oiso Y (2005) Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 28:757-758.
30. Mori Y, Tanaka T, Matsuura K, Yokoyama J, and Utsunomiya K (2011) Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). Adv Ther 28:698-706.
31. Núñez S, Venhorst J, and Kruse CG (2012) Target-drug interactions: first principles and their application to drug discovery. Drug Discov Today 17:10-22.
32. Ohno K, Amano Y, Kakuta H, Niimi T, Takakura S, Orita M, Miyata K, Sakashita H, Takeuchi M, and Komuro I, et al. (2011) Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor. Biochem Biophys Res Commun 404:434-437.
33. Papalia GA, Leavitt S, Bynum MA, Katsamba PS, Wilton R, Qiu H, Steukers M, Wang S, Bindu L, and Phogat S, et al. (2006) Comparative analysis of 10 small molecules binding to carbonic anhydrase II by different investigators using Biacore technology. Anal Biochem 359:94-105.
34. Picard F and Auwerx J (2002) PPAR(γ) and glucose homeostasis. Annu Rev Nutr 22: 167-197.
35. Picard F, Géhin M, Annicotte J, Rocchi S, Champy MF, O'Malley BW, Chambon P, and Auwerx J (2002) SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111:931-941.
36. Porcelli L, Gilardi F, Laghezza A, Piemontese L, Mitro N, Azzariti A, Altieri F, Cervoni L, Fracchiolla G, and Giudici M, et al. (2012) Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. J Med Chem 55:37-54.
37. Ramírez-Zacarías JL, Castro-Muñozledo F, and Kuri-Harcuch W (1992) Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 97:493-497.
38. Renaud JP and Delsuc MA (2009) Biophysical techniques for ligand screening and drug design. Curr Opin Pharmacol 9:622-628.
39. Rizos CV, Elisaf MS, and Liberopoulos EN (2009) Are the pleiotropic effects of telmisartan clinically relevant? Curr Pharm Des 15:2815-2832.
40. Rizos CV, Milionis HJ, Kostapanos MS, Florentin M, Kostara CE, Elisaf MS, and Liberopoulos EN (2010) Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Clin Ther 32:492-505.
41. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, and Staels B, et al. (2005) Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes 54:3442-3452.
42. Schupp M, Janke J, Clasen R, Unger T, and Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109:2054-2057.
43. Shao J, Nangaku M, Inagi R, Kato H, Miyata T, Matsusaka T, Noiri E, and Fujita T (2007) Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker. J Hypertens 25:1643-1649.
44. Shimabukuro M, Tanaka H, and Shimabukuro T (2007) Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25: 841-848.
45. Shimaya A, Kurosaki E, Shioduka K, Nakano R, Shibasaki M, and Shikama H (1998) YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes. Horm Metab Res 30:543-548.
46. Sugimoto K, Qi NR, Kazdová L, Pravenec M, Ogihara T, and Kurtz TW (2006) Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47:1003-1009.
47. Suksomboon N, Poolsup N, and Prasit T (2012) Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes. J Clin Pharm Ther 37:319-327.
48. Suwa A, Kurama T, Yamamoto T, Sawada A, Shimokawa T, and Aramori I (2010) Glucose metabolism activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes. Eur J Pharmacol 642:177-182.
49. Takagi H, Niwa M, Mizuno Y, Goto SN, and Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group (2013) Telmisartan as a metabolic sartan: the first meta-analysis of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens 7:229-235.
50. Takagi H and Umemoto T (2012a) Telmisartan increases adiponectin levels: a metaanalysis and meta-regression of randomized head-to-head trials. Int J Cardiol 155: 448-451.
51. Takagi H and Umemoto T (2012b) Telmisartan improves insulin sensitivity: a metaanalysis of randomized head-to-head trials. Int J Cardiol 156:92-96.
52. Takagi H and Umemoto T (2012c) Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: a meta-analysis of randomized head-to-head trials. Int J Cardiol 157:403-407.
53. Takenaka Y, Inoue I, Nakano T, Shinoda Y, Ikeda M, Awata T, and Katayama S (2013) A novel splicing variant of peroxisome proliferator-activated receptor-γ (Pparγ1sv) cooperatively regulates adipocyte differentiation with Pparγ2. PLoS ONE 8:e65583.
54. Tontonoz P, Hu E, and Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. Cell 79:1147-1156.
55. Velázquez-Campoy A, Ohtaka H, Nezami A, Muzammil S, and Freire E (2004). Isothermal titration calorimetry. Curr Protoc Cell Biol 23:17.8.1-17.8.24.
56. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, and Kahn CR (1996) Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93:12490-12495.
57. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, and Rosano GM (2005) Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4:6.
58. Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697-738.
59. Watanabe M, Inukai K, Sumita T, Ikebukuro K, Ito D, Kurihara S, Ono H, Awata T, and Katayama S (2010) Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. Intern Med 49:1843-1847.
60. Yamashita S, Tanaka Y, Endoh Y, Taki Y, Sakane T, Nadai T, and Sezaki H (1997) Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption. Pharm Res 14:486-491.
61. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, and Ueki K, et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295.
62. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, and Tsuboyama-Kasaoka N, et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946.
63. Yano Y, Hoshide S, Ishikawa J, Noguchi C, Tukui D, Takanori H, Tada M, Kanemaru Y, Yano A, and Ishikawa S, et al. (2007) The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to lowgrade inflammation in metabolic hypertensive patients. Am J Hypertens 20: 565-572.
64. Yao B, Collins B, and ChenM (2005) Light scattering to detect compound aggregation in screening assays. Drugs Plus Int 4:21-24.
65. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, and Reaven GM (1992) Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 231:235-240.